Antibodies - Accelerated Contract Research with the Disruptive Power of Simoa®
Can't see this email? View it online
   
  Antibodies  
  The latest antibodies news from News Medical  
 

VHH Antibodies (Nanobodies) Advantages and LimitationsHigh bioactivity target proteins for ADCs

ACROBiosystems has developed a series of ADCs target proteins with different species and tags suitable for immunization, antibody screening, affinity testing, cell-based assay analysis, and other applications. ACROBiosystems is committed to assisting you in drug development, and all SPR&BLI&ELISA protocols are available for free.

Find Out More
 
 
    Keysight Accelerated Contract Research with the Disruptive Power of Simoa®
 
Gain instant access to Simoa®, Quanterix's ultra-sensitive biomarker detection technology, with the Quanterix Accelerator Laboratory. Quanterix continually expands the limits of biomarker research by detecting protein biomarkers at the lowest possible levels. Watch this video to discover how Simoa and Quanterix's NF-Light™ assay have helped one client overcome their therapeutic development challenges.
 
Learn More
 
 
   Designed proteins assemble antibodies into modular nanocagesDesigned proteins assemble antibodies into modular nanocages
 
With cues from nature, designing functional molecules enables scientists to nanoengineer and customize for specific uses.
 
 B Cell Development
 
B Cell DevelopmentB cell development begins in the fetal liver. From 12 weeks onwards, B cell development continues in hematopoietic stem cells in the bone marrow.
 
 
 CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma
 
CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphomaA CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
 
 
 Study: CAR T cell therapy is a safe, effective therapy for high-risk large B-cell lymphoma
 
Study: CAR T cell therapy is a safe, effective therapy for high-risk large B-cell lymphomaA study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.
 
 
 Monoclonal antibody HB27 shows potent neutralizing activity against SARS-CoV-2
 
Monoclonal antibody HB27 shows potent neutralizing activity against SARS-CoV-2A new study reports a very promising anti-SARS-CoV-2 monoclonal antibody, HB27, that appears to have two distinct mechanisms of action inhibiting the virus-host cell interaction and subsequent infection.